<DOC>
	<DOCNO>NCT01861717</DOCNO>
	<brief_summary>If someone diagnose pituitary tumor cause acromegaly ( much growth hormone ) treatment surgically remove . This study two phase . The first phase provide medical treatment drug provide 3 month surgery see complication surgery reduce see whether remission improve follow surgery medical treatment . The drug administer approved FDA long-term treatment acromegaly . It routinely administer surgery , therefore experimental used way . All procedure perform research standard care exception 3 questionnaire complete visit . The second phase study 3 month 12 month surgery people go remission operation . This phase assess possible remission acromegaly resume drug treatment additional 3 9 month . The drug prescribe physician part regular medical care include part study . All procedure perform research standard care exception 3 questionnaire complete visit . The study last approximately 16 month - 3 month surgery 12 month surgery .</brief_summary>
	<brief_title>A Pilot Study Pre- Post-operative Use Somatuline Depot .</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>age 18 75 elevate serum IGF1 level age sexbased normal value failure growth hormone ( GH ) suppression &lt; 1.0 ng/ml 75 gm oral glucose tolerance test ( OGTT ) American Association Clinical Endocrinolgists ( AACE ) Acromegaly Clinical Guidelines 2004 visible pituitary adenoma ( microadenoma macroadenoma ) high quality pituitary MRI without gadolinium prior treatment acromegaly surgery , somatostatin analog pegvisomant acceptable therapy discontinue least 3 month prior study entry Age &lt; 18 &gt; 75 year acromegalic patient currently lanreotide octreotide preparation pegvisomant patient receive prior radiotherapy radiosurgery patient adenomarelated visual acuity visual field deficit optic nerve and/or chiasm compression severe optic nerve/chiasm compression set normal visual field acuity patient pituitary apoplexy define recent tumor hemorrhage and/or infarction MRI associate symptom new onset visual loss , diplopia and/or adrenal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>excess growth hormone</keyword>
	<keyword>excess GH</keyword>
	<keyword>gigantism</keyword>
	<keyword>pituitary tumor</keyword>
	<keyword>pituitary adenoma</keyword>
	<keyword>growth hormone tumor</keyword>
	<keyword>GH secrete adenoma</keyword>
	<keyword>Somatuline</keyword>
	<keyword>lanreotide</keyword>
</DOC>